Evonile Pharma Revises Debt Disclosure, Corrects Heading Error

Evonile Pharma Ltd has submitted a revised integrated filing to rectify an inadvertent omission in the heading of a table related to outstanding debt. The company clarified that the amounts disclosed for 'Total amount outstanding as on date' and 'Total financial indebtedness' should be read as ₹800 crores as of September 30, 2026. This revision does not alter the unaudited financial results or the limited review report previously submitted. The filing pertains to the quarter and half-year ended September 30, 2026.